Introduction of Regulatory Guidelines for Biosimilar Production
The increasing institution of regulatory guidelines concerning the production of biosimilars is a key factor driving the Cell Line Development Market. The World Health Organization, Food and Drug Administration, and European Medicines Agency are adopting stringent rules for the production of biosimilars, including their cell line development process. This is compelling biopharmaceutical companies to invest in advanced cell line technologies, ultimately leading to the growth of the market. Key players in the market are focusing on qualifying their master cell banks and working cell banks to meet these regulatory standards. Quality control parameters, such as stability, purity, and potency instituted as requirements for these cell banks, are directly influencing the dynamics of the market.
